Relaxin Ameliorates Fibrosis in Experimental Diabetic Cardiomyopathy
Open Access
- 3 April 2008
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 149 (7) , 3286-3293
Abstract
Fibrosis (extracellular matrix accumulation) is the final end point in diabetic cardiomyopathy. The current study evaluated the therapeutic effects of the antifibrotic hormone relaxin (RLX) in streptozotocin-treated transgenic mRen-2 rats, which undergo pathological and functional features similar to human diabetes. Twelve-week-old hyperglycemic mRen-2 rats, normoglycemic control rats, and animals treated with recombinant human gene-2 (H2) RLX from wk 10–12 were assessed for various measures of left ventricular (LV) fibrosis, hemodynamics, and function, while the mechanism of RLX’s actions was also determined. Hyperglycemic mRen-2 rats had increased LV collagen concentration (fibrosis) and gelatinase activity (all P < 0.05 vs. controls) but equivalent levels of interstitial collagenase and tissue inhibitor of metalloproteinase-1 to that measured in control rats. The increased LV fibrosis associated with diabetic animals led to significant alterations in the E/A wave ratio and E-wave deceleration time (both P < 0.05 vs. controls) in the absence of blood pressure changes, reflective of myocardial stiffness and LV diastolic dysfunction. H2-RLX treatment of diabetic rats led to significant decreases in interstitial and total LV collagen deposition (both P < 0.05 vs. diabetic group), resulting in decreased myocardial stiffness and improved LV diastolic function, without affecting nondiabetic animals. The protective effects of H2-RLX in diabetic rats were associated with a reduction in mesenchymal cell differentiation and tissue inhibitor of metalloproteinase-1 expression in addition to a promotion of extracellular matrix-degrading matrix metalloproteinase-13 (all P < 0.05 vs. diabetic group) but were independent of blood pressure regulation. These findings demonstrate that RLX is an antifibrotic with rapid-occurring efficacy and may represent a novel therapy for the treatment of diabetes.Keywords
This publication has 38 references indexed in Scilit:
- Advanced glycation end products decrease mesangial cell MMP-7: A role in matrix accumulation in diabetic nephropathy?Kidney International, 2007
- Common and unique mechanisms regulate fibrosis in various fibroproliferative diseasesJournal of Clinical Investigation, 2007
- The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic CardiomyopathyJACC, 2006
- Expression and Response to Angiotensin-Converting Enzyme Inhibition of Matrix Metalloproteinases 2 and 9 in Renal Glomerular Damage in Young Transgenic Rats with Renin-Dependent HypertensionThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive RatsHypertension, 2005
- Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivoGut, 2001
- Relaxin decreases renal interstitial fibrosis and slows progression of renal diseaseKidney International, 2001
- Relaxin and renal fibrosisKidney International, 2001
- A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR)Kidney International, 1998
- Relaxin: A pleiotropic hormoneGeneral Pharmacology: The Vascular System, 1997